AstraZeneca gets 6-mth extension to sell Meronem in India

AstraZeneca Pharma India has got an extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India for the next six months.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney master your money IThe Winning Leap SME Special
Moneycontrol

Home » News » Business

Dec 01, 2016, 10.17 PM | Source: PTI

AstraZeneca gets 6-mth extension to sell Meronem in India

AstraZeneca Pharma India has got an extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India for the next six months.

Like this story, share it with millions of investors on M3

AstraZeneca gets 6-mth extension to sell Meronem in India

AstraZeneca Pharma India has got an extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India for the next six months.

Post Your Comments

Share Cancel

| 1 Comments
AstraZeneca gets 6-mth extension to sell Meronem in India
AstraZeneca Pharma India  has got an extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India for the next six months.

"AstraZeneca Pharma India Ltd has received on December 01, 2016 a notice to extend the date of distribution arrangements for Meronem up to July 31, 2017, during which time the parties shall continue to act in accordance with the terms and conditions of the agreement,"the company said in a BSE filing.

It further added: "The extension is due to the delay in the divestment of AstraZeneca's global rights to Meronem." Meronem is anti-bacterial used for the treatment of serious infections in hospitalised patients.

In August this year, AstraZeneca Pharma India had said that it will stop selling anti-bacterial drug Meronem in India following a global deal by its parent AstraZeneca UK to sell its small molecule antibiotics business to Pfizer Inc.

The company had received a notice of termination from AstraZeneca UK conveying its decision for termination of distribution arrangements for Meronem in India.

The product is currently one of the company's principal products which generated 18 per cent total turnover of the firm in fiscal ended March 31, 2016.

Buy, Hold, Sell ? Hear it first on M3
AstraZeneca gets 6-mth extension to sell Meronem in India

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login